Search
STAAR Surgical Co
STAAAdd to Watchlist
27.790USD
-0.360-1.28%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.37BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.28%
5 Days
-5.12%
1 Month
-6.93%
6 Months
+17.75%
Year to Date
+20.36%
1 Year
+55.60%
Key Figures
28.350Open
28.590High
508.77KVolume
LossP/E TTM
55.52P/E Dynamic
--Dividend TTM
1.03%Turnover Ratio
28.150Prev. Close
27.465Low
11.73MTurnover
LossP/E Static
3.99P/B
0.00%Div Yield TTM
-4.63%ROA
30.81052wk High
1.15Volume Ratio
-20.21MNet Profit
49.40MShares
-0.4200EPS TTM
1.02Beta
-5.99%ROE
14.69052wk Low
4.00%Amplitude
73.63%Gross Margin
1.37BMarket Cap
-1.87Reward/Risk
3.07%Risk Rate
TradingKey Stock Score of STAAR Surgical Co
Currency: USD Updated: 2026-07-02Key Insights
STAAR Surgical Co's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 78 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 29.67.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
STAAR Surgical Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
STAAR Surgical Co Highlights
StrengthsRisks
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Undervalued
The company’s latest PE is -66.16, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 58.06M shares, decreasing 15.41% quarter-over-quarter.
Held by Paul Tudor Jones
Star Investor Paul Tudor Jones holds 31.04K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.45.
Analyst Rating
Based on
11
analysts
Hold
Current Rating
29.667
Target Price
+5.39%
Upside Space
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
STAAR Surgical Co Info
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
Ticker SymbolSTAA
CompanySTAAR Surgical Co
CEOFarrell (Stephen C)
Websitehttps://www.staar.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of STAAR Surgical Co (STAA)?
The current price of STAAR Surgical Co (STAA) is 27.79.
What is the symbol of STAAR Surgical Co?
The ticker symbol of STAAR Surgical Co is STAA.
What is the 52-week high of STAAR Surgical Co?
The 52-week high of STAAR Surgical Co is 30.81.
What is the 52-week low of STAAR Surgical Co?
The 52-week low of STAAR Surgical Co is 14.69.
What is the market capitalization of STAAR Surgical Co?
The market capitalization of STAAR Surgical Co is 1.37B.
Is STAAR Surgical Co (STAA) currently rated as Buy, Hold, or Sell?
According to analysts, STAAR Surgical Co (STAA) has an overall rating of signal_hold, with a price target of 29.67.
What is the Earnings Per Share (EPS TTM) of STAAR Surgical Co (STAA)?
The Earnings Per Share (EPS TTM) of STAAR Surgical Co (STAA) is -1.62.